The interaction between the Staphylococcal Protein A (SpA) domain B (the basis of the Affibody) molecule and the Fc of IgG is key to the use of Affibodies in affinity chromatography and in potential therapies against certain inflammatory diseases. Despite its importance and fourdecade history, to our knowledge this interaction has never been affinity matured. We elucidate reasons why single-substitutions in the SpA which improve affinity to Fc may be very rare, and also discover substitutions which potentially serve several engineering purposes. We used a variation of FoldX to predict changes in protein-protein-binding affinity, and produce a list of 41 single-amino acid substitutions on the SpA molecule, of which four are near wild type (wt) and five are at most a factor of four from wt affinity. The nine substitutions include one which removes lysine, and several others which change charge. Subtle modulations in affinity may be useful for modifying column elution conditions. The method is applicable to other protein-protein systems, providing molecular insights with lower workload than existing experimental techniques.
Introduction
Protein A from Staphylococcus aureus (SpA) is a virulence factor which counters the host immune system in multiple ways. SpA comprises five homologous domains joined by flexible linkers. The domains are small, easy to express and bind IgG1 with high affinity at the CH2/CH3 cleft. Of these, domain B has attracted particular interest because it is closest to the consensus sequence of all such domains, lacks methionine residues which would be susceptible to cyanogen bromide cleavage (Nilsson et al., 1987) and has been crystallized with Fc (Deisenhofer, 1981) . It is the basis of domain Z, an antibody mimetic scaffold marketed as the Affibody molecule (Löfblom et al., 2010) . The Affibody scaffold has A1V and G29A mutations with respect to domain B. This molecule without further modifications will be referred to here as wild type (wt). The purpose of G29A is to modify the N-G (asparagine-glycine) dipeptide sequence which is susceptible to hydroxylamine cleavage, turning it to N-A. G29A (Nilsson et al., 1987) also destroys binding against the fragment antigen-binding (Fab) of VH3 antibodies, which occurs at a distinct site on domain B (Fig. 1) . The A1V substitution creates an AccI DNA restriction site, originally used to polymerize domain Z, and does not affect binding (Nilsson et al., 1987) . Domain Z (or Affibody molecule) and domain B are thus very similar.
There are several reasons to engineer the interaction between SpA and Fc. SpA circulating in patient bloodstream has an antiinflammatory effect (MacLellan et al., 2011) . Five-domain SpA is the basis of the proposed PRTX-100 drug (Bernton et al., 2014) against autoimmune inflammatory diseases. The smaller Affibody molecule also has potential as a therapy against autoimmune diseases. Like SpA itself, it binds the Fc of IgG1, 2 and 4 (but not 3) with high affinity (Table I) (Goding, 1978; Bottomley et al., 1994) , on a epitope that is overlapping with the binding site of the neonatal Fc receptor (FcRn) . FcRn regulates levels of IgG in serum, by rescuing IgGs from lysosomal degradation (Roopenian and Akilesh, 2007) . This mechanism maintains a high level of autoantibodies in autoimmune diseases. Knocking out FcRn decreases levels of autoimmune IgGs, and decreases symptoms of autoimmune disease in mice (Roopenian and Akilesh, 2007) . One potential therapeutic strategy to ameliorate the symptoms associated with these debilitating diseases could be blockage of FcRn with an inhibitor, be it an antibody (Liu et al., 2007) or possibly an anti-FcRn Affibody (Seijsing et al., 2014) . Antibodies are large and hard to express, while the anti-FcRn Affibodies have relatively low affinity, no better than 12 nM (Seijsing et al., 2014) . Alternatively, one could block the FcRn-binding site on the antibody, using domain Z, the approach we consider here. Increasing the affinity of this domain could mean increased efficacy and lower dosage requirements. The Affibody molecule is also used in MabSelect affinity columns; here modified affinity could lead to advantages in purification and ease of elution. Since the Affibody has many applications, there is occasionally a need to attach prosthetic groups such as PEG. Cysteines are often used as targets for such chemical modifications; lysines are inconvenient because there are two lysines which should not be modified because they are in the Fc-binding site. It would be good to have two orthogonal functionalization sites, e.g. cysteines and lysines. With the current technique, we can remove lysines from the binding site, and then introduce them in more convenient locations for that purpose.
Despite the tremendous economic incentive, the interaction between SpA domains and IgG Fc has not been engineered to improve affinity in the literature (Cedergren et al., 1993) . In this work we discuss the possible reasons the affinity of this interaction may be difficult to increase.
Protein mutations which result in measured affinity comparable to wt are referred to as neutral. Such mutations are potentially useful for many goals in biotechnology and basic research. They appear to lie on the evolutionary trajectory connecting related proteins of different function (Wagner, 2008) . Direct effects can be obtained by introduction of a certain residue at a specific site, e.g. tryptophan, which can be used for monitoring intrinsic tryptophan fluorescence. A broader repertoire of effects can be achieved by functionalization, involving chemical modification of side chains through site specific reagents. Functionalization may require the introduction of desired side chains in specific regions of the protein and their removal from others. Reagents selective for the amino acid of interest can then be used to introduce desired features at the specific sites. For example, to extend the plasma stability of Pegvisomant via PEGylation (Abuchowski et al., 1977) at lysine residues, a lysine had to be removed from the high-affinity receptor-binding site and replaced by a alternative side chain that was expected not to influence the affinity for the receptor (although the effect was never rigorously predicted or measured) (Pradhananga et al., 2002) . The freedom to introduce functionalization sites at or near the interface can also be useful, e.g. to attach a Fluorescence Resonance Energy Transfer donor or acceptor which detects binding at the interface.
Many other characteristics can also be influenced by engineering. Proteins often need to be thermodynamically stable, soluble, not immunogenic, and/or specific. Stability can be modified by changes in the amino acid sequence, as methionines and certain dipeptide sequences are susceptible to chemical cleavage, and often need to be removed (Nilsson et al., 1987) . Sometimes the mutations have to be introduced in (Pradhananga et al., 2002) or near (Nilsson et al., 1987) protein-binding sites without loss of binding. Lastly, a subtle and controlled reduction of binding affinity can sometimes be useful, for instance to enable milder elution conditions in affinity purification.
FoldX predicts the change in free energy of protein-protein binding (Li et al., 2015) (ΔΔG) upon mutation. Binding energy comprises non-bonded (including electrostatic, van der Waals, and related), bonded (related to quantum mechanical interactions between chemically connected atoms), entropy change and potentially changes in protein protonation state upon binding . When two bound proteins separate, the interactions between the two can be replaced by interactions between protein and water. Modeling this adequately is crucial, but using explicit water is often less effective (and almost always more computationally expensive) than using implicit representations , as is done in the FoldX (Guerois et al., 2002) and other (Petukh et al., 2015) potentials. Using a variation of FoldX, we predicted ΔΔG for all possible single-substitution mutations in SpA at the Fc-binding interface, a process we call MultiScanning. We expressed single-substitution mutants with low ΔΔG ZEMu and experimentally measured the affinities against Fc. None of these increased affinity, suggesting that affinity-improving substitutions are rare for this system. We found several neutral mutations which alter interface properties such as charge and hydrophobicity. The results are applicable for engineering other protein-protein interactions for many purposes.
Results
To predict possible substitutions in the Affibody molecule which maintain affinity for Fc, we performed MultiScanning. Figure 2 shows the ΔΔG ZEMu of Fc binding resulting from all possible singleresidue substitutions in the Fc-binding site of the Affibody molecule. Coordinates for the Affibody molecule/IgG1 complex were taken from Protein Data Bank (PDB) structure 1FC2 (Deisenhofer, 1981) . Among the interface residues, we can observe that Positions 5, 6, 7, 9, 10, 11, 14, 17, 28, 31, 32, 34 and 35 have substitutions that satisfy ΔΔG ZEMu ≤ −1.0 kcal/mol (Fig. 2) .
We used ΔΔG ZEMu and qualitative criteria (see Criteria for manual selection of putative tight-binding variants) to select variants to express and evaluate using Fluorescence Activated Cell Sorting (FACS) in Round 0. We used the same manual criteria to select variants to express and evaluate by Surface Plasmon Resonance (SPR) biosensor technology in Round 1. Lastly, we used only the criterion that ΔΔG ZEMu ≤ −1.0 kcal/mol, to select mutants to evaluate by SPR in Round 2.
Round 0: Affinity estimation of manually selected variants using FACS In Round 0 we selected six variants (I31F, N28L, L17Y, K35Y, Q10L and Q9K) for evaluation by FACS (Löfblom et al., 2005) . The selection was based on ZEMu energy and visual inspection as described in the section Criteria for manual selection of putative tight-binding variants. We also selected Q10K as a negative control, based on higher ΔΔG ZEMu . ΔΔG ZEMu and visual inspection observations for Round 0 variants are given in Supplementary Table S1 .
Two of the variants, L17Y and Q9K, appeared to bind well by FACS, possibly better than wt. I31F appeared to bind with affinity only slightly lower than wt ( Supplementary Fig. S1 ). However, the variability of the measurement did not support a definitive conclusion. This motivated retesting of L17Y and Q9K by SPR in Round 1, at which point these two were found to be poor binders (Fig. 3A) .
I31F, N28L, K35Y and Q10L were eventually retested by SPR in Round 2, and also found to be poor binders. Q10K was never tested by SPR because it was a putative negative control, whereas in Round 1 we chose the already-characterized L17D (Cedergren et al., 1993) as our negative control.
The discrepancy between FACS and subsequent SPR measurements was most remarkable for I31F, L17Y and Q9K. It should however be noted that the affibodies are expressed as fusion proteins on the bacterial surface and that the flow-cytometry experiment results in avidity effects from the bivalent IgG binding to the cells. This may explain some of the discrepancy.
Round 1: Affinity measurement of manually selected variants using SPR
In Round 1 we expressed the wt, L17D negative control, L17Y and Q9K (from Round 0), and five new Affibody variants (Q9D, Q10D, Q10N, Q10H and N28Y). As in Round 0, the five new variants were selected according to Criteria for manual selection of putative tight-binding variants. ΔΔG ZEMu and visual inspection observations for Round 1 variants are given in Supplementary Table S2 . We measured the Affibody variants' affinities against human IgG1 using SPR (see Methods). A dilution series of the proteins (6.25-100 nM) was injected over immobilized IgG1, without regenerating the surface between injections (Fig. 3A) . Based on a qualitative analysis of their SPR signal levels at steady state and apparent dissociation rates, the Round 1 variants showed low (Q9D, Q9K, Q10N, Q10H, L17Y and N28Y) or undetectable (Q10D and L17D) affinity for IgG1 relative to wt Affibody molecule. Thus all Round 1 substitutions reduced the affinity of the Affibody molecule for Fc. We were not able to quantify the K D (equilibrium dissociation constants) of these mutants because they are higher (>50 nM) than half the maximal SpA concentration (100 nM) used in the experiments.
Round 2: SPR affinity measurement of variants selected on the basis of ZEMu energy only
As all the substitutions tested in Round 1 reduced the affinity between the Affibody and Fc, a new selection strategy was used. In Round 2 we expressed all the Affibody variants that satisfied ΔΔG ZEMu ≤ −1.0 kcal/mol, and which were not tested in Round 1. In the SPR analysis (see Methods) we injected the proteins as analytes at 100 nM over a sensor surface with immobilized human IgG1 (Fig. 3B) . In this experiment the surface was regenerated between each injection to make sure that no protein stuck to the surface, potentially resulting in a heterogeneous surface. The Affibody molecule variants were classified according to their interaction characteristics relative wt Affibody, here based on a qualitative analysis of their signal levels at steady state, and apparent dissociation rates (Fig. 3B,C) . Most variants exhibited qualitatively low affinities and rapid dissociation rates (Fig. 3B) . However, nine variants had higher affinities and slower dissociation rates (Fig. 3C ). This class was further evaluated quantitatively relative to wt Affibody, by injecting the proteins over immobilized IgG1 in a serial dilution experiment using 3.15-50 nM proteins, without regeneration between injections (Fig. 3D,E) . By qualitatively comparing the observed binding levels and the apparent dissociation rates of the sensorgrams, we found five variants (F5M, N6Q, K7D, Y14F, N28F) that appeared to form a subset (of the nine) with somewhat lower affinity than the wt Affibody (Fig. 3D) . The other four variants (N6F, N11F, Q32K and Q32L) were qualitatively estimated to have an affinity similar to that of wt Affibody (Fig. 3E) . To quantify the affinity (defined as K D ), we performed nonlinear regression analysis of the sensorgrams. We estimated the association and dissociation rate constants (k a and k d ) by fitting the SPR sensorgrams to a 1:1 interaction model (Table I) . Comparing the dissociation constants (K D ), the Affibody variants N6F, N11F, Q32K and N6Q had low nanomolar affinity against IgG1, near that of the wt protein. Note the final quantitative differs from the initial qualitative grouping. (Cedergren et al., 1993) , and seven Affibody variants (Q9D, Q9K, Q10D, Q10N, Q10H, L17Y and N28Y) expressed in Round 1. (B, C) Ranking of wt and 34 Affibody variants expressed in Round 2. (B) Affibody variants with relatively low affinity for human IgG1 (F5Q, N6T, Q9L, Q10A, Q10C, Q10G, Q10I, Q10L, Q10M, Q10P, Q10S, Q10T, Q10V, N11P, N28C, N28L, N28P, I31F, L34F, L34P, K35P, K35W, K35Y, L17R, Q10E), and (C) nine variants with relatively higher affinity for human IgG1, in comparison to wt Affibody (F5M, N6F, N6Q, K7D, N11F, Y14F, N28F, Q32K, Q32L). (D, E) Kinetic characterization of the nine Affibody variants with relatively higher affinity for IgG1 (Kinetic data in Table I ) and grouping into further subsets by visual inspection (grouping of N6Q and Q32L differed in final quantitative classification). (D) Medium apparent affinity (F5M, N6Q, K7D, Y14F, N28F) . (E) Near wt apparent affinity (N6F, N11F, Q32K, Q32L).
Discussion
Protein Engineering is a central topic in Biotechnology. There are many properties to be optimized in therapeutic, diagnostic, or industrial proteins. On top of such engineering goals, affinity against a specified binding partner must often be conserved or modulated. In this work we scanned an entire interface computationally and produced a short list of substitutions with low predicted binding energy.
In this demonstration, we confirmed experimentally that 9 ZEMupredicted Affibody variants were able to bind with strong affinity to human IgG1, including K7D which removed lysine, Q32K which introduced lysine elsewhere, and several that changed other properties including size, aromaticity and hydrophobicity. Four of the 9 variants were confirmed to bind with near wt affinity, however none of them had affinity significantly stronger than wt. wt Affibody molecule displays an affinity already in the low nanomolar to subnanomolar range, and the interface is dominated by the hydrophobic effect, with no direct way to create new salt bridges. The already-high affinity (Goding, 1978; Bottomley et al., 1994) and interface characteristics likely explain why further affinity improvements are difficult to attain.
In protein-protein systems, substitutions which reduce typically greatly outnumber those that increase affinity. Validation datasets of experimental ΔΔG values compiled from the literature (Moal and Fernández-Recio, 2012 ) may be enriched in affinity-increasing mutations (compared to random mutagenesis), as many investigators actively seek such mutations. Since any ΔΔG prediction method has error bars, the large number of affinity-reducing mutations means many opportunities for false positives. In a system with scarce possibilities for improving affinity, all of the predicted affinity-improving mutations could in fact be affinity-reducing or neutral. This appears to have happened in the present work.
We note that in Round 0 (comprising six putative affinityimproving single-substituted variants) and Round 1 (including two variants from Round 0, plus five new ones), we used human judgment in addition to ZEMu energy as a filter to choose mutants to express, whereas in Round 2 (comprising the four variants from Round 0 which were not tested in Round 1, plus 30 new variants) the selection was based only on a ZEMu energy cutoff (ΔΔG ZEMu ≤ −1.0 kcal/mol). All nine of the better binders (Fig. 3C) , however, were among the 30 new, systematically selected variants in Round 2. To be clear, a total of 11 variants were manually selected, of which none appear among the better binders shown in (Fig. 3C) . The nine higher-affinity substitutions were all on the outer rim (solvent-exposed portion) (Bogan and Thorn, 1998) of the interface (Fig. 4) , whereas the manually selected substitutions were all closer to the core (buried portion) of the interface (with the exception of N28L). This suggests that the reason the manually selected substitutions were unsuccessful was related to a selection bias for residue positions which were in the core, where there are more intermolecular contacts. In an optimized system with a well-packed interface core, neutral mutations may be easier to find on the rim. However though it has been shown that rim positions can be modified with a lesser energetic effect than the core positions (Bogan and Thorn, 1998) , it does not follow that all rim mutations will be neutral. For example, the substitutions N11F and Q32K have high but N11P and Q32L have low and medium affinities, respectively. Similarly N6F and N6Q have high, but N6T has low affinity. N28F has medium but N28C, L, P and Y all have low affinity. F5M has medium, but F5Q has low affinity.
We investigated the possibility of non-perturbative effects of the mutations on SpA monomer stability with Molecular Dynamics (MD), however secondary structure changes (data not shown) did not correlate with experimentally observed affinity changes. MD was not used by any of the competitors in the CAPRI Round 26 scoring competition (Moretti et al., 2013) , and in our hands deteriorates the results of a subsequent FoldX calculation (Dourado and Flores, 2014) . Other non-perturbative effects, for example related to the interaction with Fc, may be at play.
The rarity of neutral compared with affinity-reducing substitutions, combined with the known error range of ZEMu, means that reduced-affinity variants appearing on the low side of their ΔΔG ZEMu error bars are likely to outnumber neutral or increasedaffinity variants. This explains why several substitutions have predicted affinity higher than wt (Fig. 2) when experimentally none were significantly higher than wt.
ZEMu found that Position 10 had an unusually large number of predicted low-energy variants; we expressed 11 of them and found none were good binders. This many false positives at a single position has statistical significance (P-value of 0.04 by the cumulative hypergeometric function). The explanation could be that the wt Affibody molecule stability was overestimated by ZEMu, making many of the variants appear comparatively more favorable. However not all cases in which many substitutions at a single position are predicted to be favorable, will be artifacts. There are documented cases in which the wt residue type at a certain position appears to disfavor binding, compared to Alanine (Cunningham and Wells, 1989) or potentially many possible substitutions.
Our findings related to Position 10 underscore the merit of limiting the number of substitutions that are expressed at a single position; in any case only one will likely be used in the end. Conversely one may consider testing at least one substitution at each position, even if all substitutions at that position have high energy, because the wt energy could be underestimated. We suggest expressing only single-substitution variants initially, as one affinity-destroying, expressed together with an affinity-improving substitution, may mask the latter. Expressing a sufficient number is important; the seven substitutions we expressed in Round 1 were all poor binders whereas the more numerous variants evaluated in Round 2 included several neutral substitutions. An objective selection criterion is important, as again no neutral substitutions were found in the manually selected Rounds 0 and 1, whereas Round 2, based on ZEMu energy alone, was profitable.
Residue conservation was not useful for choosing mutations in this case. As mentioned Domain Z is based on the consensus sequence. The nine mutations with high and medium affinity were at Positions 5, 6, 7, 11, 14, 28 and 32 (Table I) , which are absolutely conserved according to the alignment of (Santos-Júnior et al., 2016) . However all positions in this sequence region are highly or absolutely conserved, since all the sequences are aligned across strains of Staphylococcus aureus (Santos-Júnior et al., 2016) . Aligning across structural domains in a single strain also shows high conservation. Here positions 5, 6, 7, 11 are highly conserved, but the best mutants do not correspond to an observed amino acid polymorphism; 14, 28, 32 are absolutely conserved (Nilsson et al., 1987) .
Our results suggest there are few single-substitution mutations to be made in SpA that would increase affinity against Fc, due to an already-high affinity (reported here and elsewhere) (Santos-Júnior et al., 2016) and a mostly hydrophobic interface spanned by only four hydrogen bonds (Goding, 1978; Bottomley et al., 1994) with no clear potential to form new salt bridges (Fig. 5) . We did find nine SpA mutations which keep Fc binding in the range of 1-4X of wt affinity but which change other interface properties. Some of the mutants which made reductions in affinity (some very subtle, others greater) may be useful to enable gentler (e.g. pH closer to neutral) elution conditions in SpA affinity chromatography. Since we used ZEMu screening, the number of proteins expressed and evaluated was relatively small, making this an inexpensive method. We proposed rules for productively selecting mutants to test.
Materials and methods

Prediction of binding energy
ZEMu is a model building method, that is it can generate an energyminimized mutant structure given coordinates of the corresponding wt structure (Deisenhofer, 1981) . In ZEMu, we specified a flexibility zone of five residues, consecutive in sequence, centered about the residue to be substituted. Residues in this zone had torsional freedom, while the remainder of the protein was rigid and fixed. We also specified a physics zone inside of which PARM99 electrostatic and van der Waals forces were active. The physics zone included all residues within 14Å of the flexibility zone. We then energyminimized by computing the dynamics of this system for 20 ps. In prior work we found this was enough to ensure convergence; fluctuations in individual results can be expected with slight variation of run time and other conditions, though average values (RMSE) are not noticeably affected (Dourado and Flores, 2014) . The protein-protein interaction energy of the thus-equilibrated complex was then evaluated with FoldX3 (Dourado and Flores, 2014) . We conducted the equilibration and FoldX calculation for the wt and the mutant complex to obtain ΔG wt and ΔG mutant , respectively. The difference provided an estimate of ΔΔG experiment (Guerois et al., 2002) :
ZEMu gave an improvement in the RMSE of a subsequent FoldX3 calculation (Dourado and Flores, 2014) . Performance of FoldX4 (the current release) differs somewhat from that of FoldX3 (Xiong et al., 2017) , and does not appear to benefit from ZEMu.
MultiScanning
We define MultiScanning as in silico saturation (i.e. to all 19 alternate amino acid types) mutagenesis (and ΔΔG prediction) using ZEMu, over the entire protein-binding site of one of the interacting proteins. The binding site is defined as all residues within 6 Å of their interaction partner. In the case of the Affibody molecule this means 25 residue positions, for a total of 425 mutations. MultiScanning is implemented in our breeder job management software, which uses MMB not only as an executable but also as an Application Programming Interface. We used PDB structure 1FC2 (Xiong et al., 2017) as input for the ΔΔG prediction. Affibody: gray cartoon. High-, medium-and low-affinity Affibody substitutions: thick transparent red, medium transparent orange and thin opaque blue licorice, respectively; residue substitution labels also correspondingly red, orange and blue. Note high-and medium-affinity substitutions are on the solvent-exposed rim of the interface, whereas most low-affinity substitutions are in the interface core. Manually selected substitutions: balls colored by atom type. Note all manually selected substitutions are low affinity, though medium-affinity N28F shares she same position as manually selected N28Y. Note also that manually selected substitutions are in the interface core, except for N28Y. Near-neutral substitutions are harder to find in the interface core.
Criteria for manual selection of putative tight-binding variants
In Rounds 0 and 1 we selected single mutants of 1FC2 based on the following quantitative and qualitative criteria:
• ΔΔG ZEMu ≤ −1.0 kcal/mol.
• Do not mutate to methionine, proline, or glycine.
• Do not mutate from proline or glycine.
• Rationalizable by visual inspection, in terms of arguable physical interactions.
• Include as many different residue positions as possible (avoid multiple substitutions at a single site).
We avoided prolines and glycines to preserve backbone structure, and methionines to prevent unwanted oxidation to methionine sulfoxide (MetO). Rationalization by visual inspection refers to examining the equilibrated structure and seeking to explain the obtained ΔΔG ZEMu . We identified possible favorable electrostatic, van der Waals, electrostatic, hydrogen-bonding and hydrophobic interactions (or lack of interactions) between the substituted residue and neighboring residues on Fc. By applying these selection criteria we obtained lists of selected single mutants. These are given, along with the qualitative results of our visual inspection, in Supplementary  Tables S1 and S2 , for Rounds 0 and 1, respectively.
Protein expression and purification
Wild type and variants of Affibody molecule sequence were generated by gene synthesis and cloned into the pET-19b plasmid (containing ampicillin resistance and a lacI promoter) by Genscript. The genes were transformed into BL21-DE3. The cells were grown in TB (Terrific broth) supplemented with 2 mM MgCl 2 , 100 μg/ml ampicillin and a trace-element mixture (50 μM FeCl 3 , 20 μM CaCl 2 , 10 μM MnCl 2 , 10 μM ZnCl 2 , 2 μM CoCl 2 , 2 μM CuCl 2 , 2 μM NiCl 2 , 2 μM Na 2 MoO 4 , 2 μM Na 2 SeO 3 and 2 μM H 3 BO 3 ). At OD600~0.6 we induced the cells by adding 1 mM IPTG and incubated for 4 h at room temperature. The cells where harvested by centrifugation and frozen at −80°C until purification.
The cell pellet was resuspended in 10 mL extraction buffer (20 mM Sodium phosphate, pH 8, 500 mM NaCl, 20 mM imidazole, 0.9 mg/ml lysozyme, 0.14 mg/ml DNase I, 1 mM EDTA and 0.5% w/v Triton X-100). The cell suspension was incubated at room temperature with constant agitation for 1 h followed by centrifugation at 4200 g at 4°C for 20 min. The clarified lysate was added to 0.5 ml Ni sepharose HP slurry (GE Healthcare) and allowed to bind for 1 h with constant agitation. We followed with two washing steps with 20 column volumes of wash buffer buffer (20 mM Sodium phosphate, pH 8, 500 mM NaCl, 20 mM imidazole). We then eluted the column with wash buffer supplemented with 500 mM imidazole, 0.5 ml fractions were collected and stored at −80°C.
Buffer exchanges of the proteins were performed using Pierce centrifuge columns from Thermo Fischer. Buffer exchanges of the proteins were performed using Zeba™ desalting centrifuge columns from Thermo Fischer. Proteins were transferred to SPR running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA pH 7.4) and IgG1 to 20 mM HEPES buffer, pH7.4. Concentration measurement of proteins was done by Bicinchoninic Acid (BCA) assay.
Fluorescence activated cell Sorting
On-cell affinity determination was analyzed using Gallios flow cytometer (Beckman Coulter, Indianapolis, IN, US) and has been previously described (Fleetwood et al. 2014) . Briefly, 20 μl of cells from induced culture were spun down and labeled with 4.3 nM biotinylated human IgG and incubated on rotamixer for 45 min. The excess IgG was subsequently washed away. Detection of IgG binding and cell expression was done by labeling cells with 10 μg/ml Strepavidin R-phycoerythrin (Invitrogen, Göteborg, Sweden) and 10 μg/ml human serum albumin-alexa488, this was incubated on ice for 25 min. The cells were transferred to 5 ml round bottomed falcon tube and analyzed using a Gallios flow cytometer.
SPR measurements
SPR measurements were carried out at 25°C using a Biacore T200 instrument (Biacore AB, Uppsala, Sweden). IgG1 purchased from Sigma Aldrich (Human IgG1, Kappa, product number I 5154) was immobilized to a CM5 chip by standard amine coupling to 6730 RU (Round 1) or 6900 RU (Round 2) using 10 mM sodium acetate buffer pH 5 as immobilization buffer. Affibody variants were injected either as one single concentration (100 nM) or in single cycle kinetic experiments, where five concentrations of the analyte run in HBS-EP running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% v/v Tween 20 pH 7.4) using a flow rate of 30 μl/min. Instead of using regeneration to clean the surface (observed as returning to baseline between sample runs), long stabilizing periods of 1800 s and 3 buffer injections were performed between sample runs. The sensorgrams were corrected for buffer bulk effects and unspecific binding of the samples to the chip matrix by blank and reference surface subtraction (subtraction of inactivated and deactivated flow cell channel). The data were analyzed using Biacore T200 evaluation software version 1.0. Simple 1:1 binding models were used for curve-fitting depending on the analysis. 
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